Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.61 |
| ▸ | PARP1 | P09874 | 6/20 | 0.59 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | PARP3 | Q9Y6F1 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | TNKS | O95271 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4743261 | 0.86 | HSD17B10 (0.69) | KDM4EALDH1A1MAPTSMN1; SMN2HSD17B10 | |
| SCHEMBL20355600 | 0.86 | PARP1 (0.72) | KDM4EALDH1A1MAPTSMN1; SMN2PARP1 | |
| SCHEMBL29040013 | 0.84 | PARP1 (0.65) | KDM4EMAPTSMN1; SMN2TNKS2PARP1 | |
| SCHEMBL29040009 | 0.82 | PARP1 (0.62) | KDM4EMAPTSMN1; SMN2TNKS2PARP1 | |
| SCHEMBL29040046 | 0.82 | PARP1 (0.62) | KDM4EMAPTSMN1; SMN2TNKS2PARP1 | |
| SCHEMBL18824358 | 0.81 | PARP1 (0.64) | KDM4EALDH1A1MAPTSMN1; SMN2TNKS2 | |
| SCHEMBL6345103 | 0.81 | ALDH1A1 (0.97) | KDM4EALDH1A1MAPTSMN1; SMN2HSD17B10 | |
| SCHEMBL4743132 | 0.79 | TNKS (0.65) | ALDH1A1SMN1; SMN2HSD17B10TNKS2PARP2 | |
| SCHEMBL9145061 | 0.79 | RAB9A (0.70) | KDM4EALDH1A1MAPTSMN1; SMN2TNKS2 | |
| SCHEMBL2180069 | 0.77 | RAB9A (0.63) | KDM4EALDH1A1MAPTSMN1; SMN2TNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713966-B2 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713966-B2 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713966-B2 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| EP-2134693-A2 | METALLOPROTEASE INHIBITORS CONTAINING A HETEROCYCLIC MOIETY | Alantos Pharmaceuticals Holding, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-2094671-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | Alantos Pharmaceuticals Holding, Inc. (US) | 2009-09-02 | — | — | EP | disclosed |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | GEGE CHRISTIAN | 2008-10-23 | — | — | US | disclosed |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | GEGE CHRISTIAN | 2008-10-23 | — | — | US | disclosed |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | GEGE CHRISTIAN | 2008-10-23 | — | — | US | disclosed |
| WO-2008109178-A1 | METALLOPROTEASE INHIBITORS CONTAINING A SQUARAMIDE MOIETY | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109178-A1 | METALLOPROTEASE INHIBITORS CONTAINING A SQUARAMIDE MOIETY | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109181-A2 | METALLOPROTEASE INHIBITORS CONTAINING A HETEROCYCLIC MOIETY | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109181-A2 | METALLOPROTEASE INHIBITORS CONTAINING A HETEROCYCLIC MOIETY | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221095-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221095-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221095-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221128-A1 | Metalloprotease inhibitors containing a squaramide moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221128-A1 | Metalloprotease inhibitors containing a squaramide moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221128-A1 | Metalloprotease inhibitors containing a squaramide moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| WO-2008063668-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008063668-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221128-A1 | Metalloprotease inhibitors containing a squaramide moiety | MMP11, MMP13, MMP14 | KDM4E 685/4885ALDH1A1 2056/4885MAPT 4194/4885 |
| US-20080221095-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | MMP13, MMP11, MMP3 | KDM4E 572/4885ALDH1A1 1569/4885MAPT 4420/4885 |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | KDM4E 1572/4885ALDH1A1 1871/4885MAPT 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.